Multi-targeting NGR-modified liposomes recognizing glioma tumor cells and vasculogenic mimicry for improving anti-glioma therapy
Metrics: PDF 1292 views | HTML 1113 views | ?
Dan Huang1,2, Shuang Zhang1,2, Ting Zhong1,2, Wei Ren1,2, Xin Yao1,2, Yang Guo1,2, Xiao-Chuan Duan1,2, Yi-Fan Yin2, Shu-Shi Zhang2, Xuan Zhang1,2
1Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
2Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
Xuan Zhang, email: email@example.com
Keywords: NGR, combretastatin A4, vascular mimicry, glioma, anti-tumor activity
Received: March 31, 2016 Accepted: May 16, 2016 Published: June 07, 2016
Like the anti-angiogenic strategy, anti-vascular mimicry is considered as a novel targeting strategy for glioma. In the present study, we used NGR as a targeting ligand and prepared NGR-modified liposomes containing combretastatin A4 (NGR-SSL-CA4) in order to evaluate their potential targeting of glioma tumor cells and vasculogenic mimicry (VM) formed by glioma cells as well as their anti-VM activity in mice with glioma tumor cells. NGR-SSL-CA4 was prepared by a thin-film hydration method. The in vitro targeting of U87-MG (human glioma tumor cells) by NGR-modified liposomes was evaluated. The in vivo targeting activity of NGR-modified liposomes was tested in U87-MG orthotopic tumor-bearing nude mice. The anti-VM activity of NGR-SSL-CA4 was also investigated in vitro and in vivo. The targeting activity of the NGR-modified liposomes was demonstrated by in vitro flow cytometry and in vivo biodistribution. The in vitro anti-VM activity of NGR-SSL-CA4 was indicated in a series of cell migration and VM channel experiments. NGR-SSL-CA4 produced very marked anti-tumor and anti-VM activity in U87-MG orthotopic tumor-bearing mice in vivo. Overall, the NGR-SSL-CA4 has great potential in the multi-targeting therapy of glioma involving U87-MG cells, and the VM formed by U87-MG cells as well as endothelial cells producing anti-U87-MG cells, and anti-VM formed by U87-MG cells as well as anti-endothelial cell activity.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.